Daridorexant
http://dbpedia.org/resource/Daridorexant an entity of type: Thing
Daridorexant ist ein Arzneistoff aus der Gruppe der Orexinrezeptor-Antagonisten. Er wurde in den USA im Januar 2022 und in der EU im April 2022 unter dem Namen Quviviq zur Behandlung von Schlafstörungen zugelassen. Das Mittel wird oral gegeben.
rdf:langString
Даридорексант — антагонист орексиновых рецепторов, используемый как снотворное средство. Одобрен для применения: США (2022).
rdf:langString
Daridorexant, sold under the brand name Quviviq, is an orexin antagonist medication which is used for the treatment of insomnia. Daridorexant is taken by mouth. Side effects of daridorexant include headache, somnolence, and fatigue. The medication is a dual orexin receptor antagonist (DORA). It acts as a selective dual antagonist of the orexin receptors OX1 and OX2. Daridorexant has a relatively short elimination half-life of 8 hours and a time to peak of about 1 to 2 hours. It is not a benzodiazepine or Z-drug and does not interact with GABA receptors, instead having a distinct mechanism of action.
rdf:langString
rdf:langString
Daridorexant
rdf:langString
Daridorexant
rdf:langString
Даридорексант
xsd:integer
57716248
xsd:integer
1124842465
rdf:langString
Daridorexant hydrochloride
<second>
-7200.0
rdf:langString
None
<perCent>
62.0
xsd:integer
23
xsd:integer
1505484
1792993
xsd:integer
4297590
4650216
xsd:integer
64854514
xsd:integer
1
rdf:langString
DB15031
<second>
28800.0
rdf:langString
Feces: ~57%
rdf:langString
Urine: ~28%
xsd:integer
23
rdf:langString
as HCl
rdf:langString
[-2--2-methylpyrrolidin-1-yl]-[5-methoxy-2-phenyl]methanone
rdf:langString
D11886
rdf:langString
D11887
rdf:langString
Schedule IV
rdf:langString
Extensive
xsd:integer
6
xsd:integer
2
xsd:integer
91801202
91809208
rdf:langString
CC1=CCl
xsd:integer
1
rdf:langString
NBGABHGMJVIVBW-QHCPKHFHSA-N
rdf:langString
Nemorexant; ACT-541468
rdf:langString
Quviviq
xsd:integer
9
rdf:langString
LMQ24G57E9
xsd:integer
250
rdf:langString
Daridorexant ist ein Arzneistoff aus der Gruppe der Orexinrezeptor-Antagonisten. Er wurde in den USA im Januar 2022 und in der EU im April 2022 unter dem Namen Quviviq zur Behandlung von Schlafstörungen zugelassen. Das Mittel wird oral gegeben.
rdf:langString
Daridorexant, sold under the brand name Quviviq, is an orexin antagonist medication which is used for the treatment of insomnia. Daridorexant is taken by mouth. Side effects of daridorexant include headache, somnolence, and fatigue. The medication is a dual orexin receptor antagonist (DORA). It acts as a selective dual antagonist of the orexin receptors OX1 and OX2. Daridorexant has a relatively short elimination half-life of 8 hours and a time to peak of about 1 to 2 hours. It is not a benzodiazepine or Z-drug and does not interact with GABA receptors, instead having a distinct mechanism of action. Daridorexant was approved for medical use in the United States in January 2022 and became available in May 2022. It was approved in the European Union in April 2022, and is the first orexin receptor antagonist to become available in European Union. The medication is a schedule IV controlled substance in the United States and may have a modest potential for misuse.
rdf:langString
Даридорексант — антагонист орексиновых рецепторов, используемый как снотворное средство. Одобрен для применения: США (2022).
rdf:langString
Daridorexant
<second>
28800.0
xsd:integer
11648
rdf:langString
Rx-only
rdf:langString
NS2
<perCent>
99.7
xsd:float
62.0
xsd:nonNegativeInteger
39081
rdf:langString
Quviviq
xsd:string
1505484-82-1
xsd:string
1792993-84-0
xsd:string
4297590
4650216
xsd:string
DB15031
xsd:string
9X9581N56R
xsd:string
LMQ24G57E9
xsd:string
D11886
D11887
xsd:string
91801202
